Cite

HARVARD Citation

    Lucas, M. et al. (n.d.). BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC. European journal of cancer. pp. S22-. [Online]. 
  
Back to record